FRACTYL HEALTH, INC.
About FRACTYL HEALTH, INC.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$141.0M
- Total assets
- $121.4M
- Market cap
- $107.7M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Cost of revenue
- $0
- Operating expenses
- $96.8M
- Operating income
- -$96.8M
- Income tax
- $0
- Net income
- -$141.0M
- EPS (basic)
- $-1.86
- EPS (diluted)
- $-1.86
Balance sheet
- Total assets
- $121.4M
- Current assets
- $87.6M
- Total liabilities
- $111.9M
- Current liabilities
- $18.3M
- Shareholders’ equity
- $9.5M
Cash flow
- Operating cash flow
- -$90.3M
- Investing cash flow
- -$557.0K
- Financing cash flow
- $105.0M
- Net cash flow
- $14.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $107.7M
- EPS (diluted)
- $-1.86
- Shares outstanding
- 160.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 2, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $141.0M.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review FRACTYL HEALTH, INC..
Write a review
News about FRACTYL HEALTH, INC.
News & sentiment via Polygon.io
